SOURCE: Cardiovascular Sciences

April 16, 2008 08:06 ET

Cardiovascular Sciences, Inc. Negotiates Agreement With GSN

ORLANDO, FL--(Marketwire - April 16, 2008) - The board of directors of Cardiovascular Sciences, Inc. (PINKSHEETS: CVSC) (the "Company") is pleased to announce that the company has negotiated an agreement with Garden State Nutritionals, Inc. (GSN) of West Caldwell, NJ. Cardiovascular Sciences, Inc. is a client company of the award winning University of Central Florida's Technology Incubator program. GSN, a division of Vitaquest International, Inc., is one of the world's leading manufacturers of nutritional products.

The agreement sets out the terms under which GSN will manufacture and deliver a powerful and proprietary anti-aging, antioxidant nutritional supplement for the Company. "We are excited to introduce a product to the market that compares very favorably and we feel surpasses the best antioxidant supplement currently on the market," director John Martin expresses. Mr. Martin is the founder and past president of Weightloss Forever International, Inc. and the developer of their very successful line of weight loss supplements.

The Company's CEO and president, Dr. Larry Hooper, exclaims, "We have formulated a very complete, unique and comprehensive antioxidant supplement. The specific formulation allows us to legitimately claim beneficial medical effects."

The Company will market this unique new supplement through the operations of Medical Technologies Enterprises, Inc. The Company has recently assumed the operations of Med Tech Enterprises and will continue to investigate, research and introduce new offerings as unique and effective products are developed.

About Cardiovascular Sciences

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals. The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development.

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

Contact Information

  • For more information contact:
    Cardiovascular Sciences Investor Relations